Prediction of relapse in paediatric pre‐B acute lymphoblastic leukaemia using a three‐gene risk index

Despite high cure rates 25% of children with acute lymphoblastic leukaemia (ALL) relapse and have dismal outcome. Crucially, many are currently stratified as standard risk (SR) and additional markers to improve patient stratification are required. Here we have used diagnostic bone marrow specimens from 101 children with pre‐B ALL to examine the use of gene expression profiles (GEP) as predictors of long‐term clinical outcome. Patients were divided into two cohorts for model development and validation based on availability of specimen material. Initially, GEP from 55 patients with sufficient material were analysed using HG‐U133A microarrays, identifying an 18‐gene classifier (GC) that was more predictive of outcome than conventional prognostic parameters. After feature selection and validation of expression levels by quantitative reverse transcription polymerase chain reaction (qRT‐PCR), a three‐gene qRT‐PCR risk index [glutamine synthetase (GLUL), ornithine decarboxylase antizyme inhibitor (AZIN), immunoglobulin J chain (IGJ)] was developed that predicted outcome with an accuracy of 89% in the array cohort and 87% in the independent validation cohort. The data demonstrate the feasibity of using GEP to improve risk stratification in childhood ALL. This is particularly important for the identification of patients destined to relapse despite their current stratification as SR, as more intensive front‐line treatment options for these individuals are already available.

[1]  Young Ho Suh,et al.  Stable siRNA-mediated silencing of antizyme inhibitor: regulation of ornithine decarboxylase activity. , 2005, Biochemical and biophysical research communications.

[2]  L. Shantz,et al.  Ornithine decarboxylase induction in transformation by H-Ras and RhoA. , 1998, Cancer research.

[3]  S. Korsmeyer,et al.  Human J chain gene. Structure and expression in B lymphoid cells , 1985, The Journal of experimental medicine.

[4]  P. Bodine,et al.  Glucocorticoids induce glutamine synthetase expression in human osteoblastic cells: a novel observation in bone. , 2004, Bone.

[5]  Wei Zhang,et al.  Combination of 5-Fluorouracil and N1,N11-Diethylnorspermine Markedly Activates Spermidine/Spermine N1-Acetyltransferase Expression, Depletes Polyamines, and Synergistically Induces Apoptosis in Colon Carcinoma Cells* , 2005, Journal of Biological Chemistry.

[6]  Richards,et al.  The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the Medical Research Council UKALLR1 study , 2000, British journal of haematology.

[7]  M. Relling,et al.  Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. , 2005, Cancer cell.

[8]  R. Gentleman,et al.  Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. , 2004, Blood.

[9]  J. Chessells.  Relapsed lymphoblastic leukaemia in children: a continuing challenge. , 1998, British journal of haematology.

[10]  W. Bleyer,et al.  Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995 , 2000, Leukemia.

[11]  J. Downing,et al.  Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.

[12]  C. Pui,et al.  Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[14]  Stuart G. Baker,et al.  Identifying genes that contribute most to good classification in microarrays , 2006, BMC Bioinformatics.

[15]  T. Taylor.  A group experience. , 1990, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[16]  J. Chessels.  RELAPSED LYMPHOBLASTIC LEUKAEMIA IN CHILDREN: A CONTINUING CHALLENGE , 1998 .

[17]  K. Seeger,et al.  Relapse of TEL-AML1--positive acute lymphoblastic leukemia in childhood: a matched-pair analysis. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Katrin Hoffmann,et al.  Gene expression levels assessed by oligonucleotide microarray analysis and quantitative real-time RT-PCR – how well do they correlate? , 2005, BMC Genomics.

[19]  G. Dini,et al.  Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies. , 2000, Haematologica.

[20]  J. Harmon,et al.  Glutamine synthetase induction by glucocorticoids in the glucocorticoid‐sensitive human leukemic cell line CEM‐C7 , 1982, Journal of cellular physiology.

[21]  P. Bühlmann,et al.  Gene expression profiles and risk stratification in childhood acute lymphoblastic leukemia , 2004 .

[22]  A. Buchmann,et al.  A beta-catenin-dependent pathway regulates expression of cytochrome P450 isoforms in mouse liver tumors. , 2004, Carcinogenesis.

[23]  G. Dini,et al.  Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies. , 2000, Haematologica.

[24]  Cheng Cheng,et al.  Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. , 2004, The New England journal of medicine.

[25]  Thomas Flohr,et al.  Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. , 2005, Blood.

[26]  Katrin Hoffmann,et al.  Translating microarray data for diagnostic testing in childhood leukaemia , 2006, BMC Cancer.

[27]  Jan Kitajewski,et al.  New targets of β-catenin signaling in the liver are involved in the glutamine metabolism , 2002, Oncogene.

[28]  C. Willman.  Discovery of novel molecular classification schemes and genes predictive of outcome in leukemia. , 2004, The hematology journal : the official journal of the European Haematology Association.

[29]  J. Cleveland,et al.  Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. , 2005, Cancer cell.

[30]  J. Downing,et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.

[31]  Martin J Firth,et al.  The gene expression signature of relapse in paediatric acute lymphoblastic leukaemia: implications for mechanisms of therapy failure , 2005, British journal of haematology.

[32]  M. Xiong,et al.  Recursive partitioning for tumor classification with gene expression microarray data , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Benarous,et al.  Overexpression of human βTrCP1 deleted of its F box induces tumorigenesis in transgenic mice , 2005, Oncogene.

[34]  Martin J Firth,et al.  Gene expression levels in small specimens from patients detected using oligonucleotide arrays , 2005, Molecular biotechnology.

[35]  Richard S Larson,et al.  Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2007, Blood.

[36]  A. Dupuy,et al.  Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. , 2007, Journal of the National Cancer Institute.

[37]  J. Chessells.  Recent advances in management of acute leukaemia , 2000, Archives of disease in childhood.

[38]  S. Knudsen,et al.  Prediction of immunophenotype, treatment response, and relapse in childhood acute lymphoblastic leukemia using DNA microarrays , 2004, Leukemia.

[39]  M. Relling,et al.  Treatment of Childhood Acute Lymphoblastic Leukaemia , 1988, The Lancet.

[40]  Katrin Hoffmann,et al.  Identification of novel molecular prognostic markers for paediatric T‐cell acute lymphoblastic leukaemia , 2007, British journal of haematology.